FDA Approves MACITENTAN — Amneal Pharmaceuticals NY LLC
Amneal Pharmaceuticals NY LLC secured FDA approval for oral MACITENTAN on June 8, 2026, a strategic move expected to diversify the company’s portfolio and intensify competition within the oral endothelin receptor antagonist market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day